IL283422A - Methods for treating or preventing asthma by administering an il-4r antagonist - Google Patents
Methods for treating or preventing asthma by administering an il-4r antagonistInfo
- Publication number
- IL283422A IL283422A IL283422A IL28342221A IL283422A IL 283422 A IL283422 A IL 283422A IL 283422 A IL283422 A IL 283422A IL 28342221 A IL28342221 A IL 28342221A IL 283422 A IL283422 A IL 283422A
- Authority
- IL
- Israel
- Prior art keywords
- antagonist
- treating
- administering
- maintenance doses
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
To provide methods for treating and/or preventing asthma and related conditions.SOLUTION: Disclosed is a method for treating moderate-to-severe uncontrolled asthma in a subject in need thereof, comprising administering a combination therapy comprising: i) one or more maintenance doses of an inhaled corticosteroid (ICS); ii) one or more maintenance doses of a long acting β2 adrenoceptor agonist; iii) a loading dose of about 400-600 mg of an interleukin-4 receptor (IL-4R) antagonist; and iv) one or more maintenance doses of about 200-300 mg of the IL-4R antagonist, where the ICS and LABA are administered for the duration of administration of the IL-4R antagonist.SELECTED DRAWING: None
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943019P | 2014-02-21 | 2014-02-21 | |
EP14306413 | 2014-09-15 | ||
US201462077669P | 2014-11-10 | 2014-11-10 | |
PCT/US2015/016852 WO2015127229A1 (en) | 2014-02-21 | 2015-02-20 | Methods for treating or preventing asthma by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
IL283422A true IL283422A (en) | 2021-06-30 |
Family
ID=66624883
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL247290A IL247290B (en) | 2014-02-21 | 2016-08-16 | Methods for treating or preventing asthma by administering an il-4r antagonist |
IL283422A IL283422A (en) | 2014-02-21 | 2021-05-25 | Methods for treating or preventing asthma by administering an il-4r antagonist |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL247290A IL247290B (en) | 2014-02-21 | 2016-08-16 | Methods for treating or preventing asthma by administering an il-4r antagonist |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP6893265B2 (en) |
IL (2) | IL247290B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US20140328839A1 (en) * | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
EP4324479A3 (en) * | 2012-08-21 | 2024-04-24 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
-
2016
- 2016-08-16 IL IL247290A patent/IL247290B/en active IP Right Grant
-
2020
- 2020-03-04 JP JP2020036331A patent/JP6893265B2/en active Active
-
2021
- 2021-05-25 IL IL283422A patent/IL283422A/en unknown
- 2021-05-28 JP JP2021089717A patent/JP7343547B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL247290B (en) | 2021-06-30 |
JP7343547B2 (en) | 2023-09-12 |
JP2021130695A (en) | 2021-09-09 |
JP2020105193A (en) | 2020-07-09 |
JP6893265B2 (en) | 2021-06-23 |
IL247290A0 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004828A (en) | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy. | |
NZ748451A (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
MX2015002378A (en) | Anxiolytic composition, formulation and method of use. | |
EA033113B1 (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
MX366197B (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs. | |
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502046B1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX2017000366A (en) | Combination therapy for cancer. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
BR112019002461A2 (en) | Dosage regimen for solid tumor treatment | |
MX2016006179A (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use. | |
MX2022015629A (en) | Use of vibegron to treat overactive bladder. | |
MX2019001467A (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer. | |
MX2018006779A (en) | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-y l)-piperidine-2,6-dione. | |
IL283324A (en) | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
MA39599A (en) | Dosage and administration anti-egfr therapeutics | |
IL283422A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
AR102494A1 (en) | METHODS TO TREAT EYE DISEASES | |
UA94010U (en) | Method for treating adenomyosis in women | |
UA111014C2 (en) | Method for treating generalized anxiety disorder in cancer patients with intestinal stoma | |
UA104733U (en) | A method of treating gastropathy in patients with chronic obstructive pulmonary disease | |
Fabbrocini | EMPACT syndrome: 2 case reports | |
UA105586U (en) | Method for treating hepatic encephalopathy |